Nymox Pharmaceutical Corporation Company Profile (NASDAQ:NYMX)

About Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Nymox Pharmaceutical Corporation logoNymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex conducts research and development, and manufacturing for NicAlert and TobacAlert.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NYMX
  • CUSIP: N/A
  • Web: www.nymox.com
Capitalization:
  • Market Cap: $203.71 million
  • Outstanding Shares: 52,367,000
Average Prices:
  • 50 Day Moving Avg: $3.67
  • 200 Day Moving Avg: $3.87
  • 52 Week Range: $2.67 - $5.10
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $180,185.00
  • Price / Sales: 1,130.55
  • Book Value: ($0.01) per share
  • Price / Book: -389.00
Profitability:
  • EBIDTA: ($11,190,000.00)
  • Net Margins: -6,394.07%
  • Return on Assets: -683.93%
Debt:
  • Debt-to-Equity Ratio: -0.92%
  • Current Ratio: 0.94%
  • Quick Ratio: 0.94%
Misc:
  • Average Volume: 182,302 shs.
  • Beta: 0.86
  • Short Ratio: 23.92
 

Frequently Asked Questions for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

What is Nymox Pharmaceutical Corporation's stock symbol?

Nymox Pharmaceutical Corporation trades on the NASDAQ under the ticker symbol "NYMX."

How were Nymox Pharmaceutical Corporation's earnings last quarter?

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) released its earnings results on Friday, November, 14th. The company reported ($0.02) EPS for the quarter. The firm earned $0.08 million during the quarter. View Nymox Pharmaceutical Corporation's Earnings History.

When will Nymox Pharmaceutical Corporation make its next earnings announcement?

Nymox Pharmaceutical Corporation is scheduled to release their next quarterly earnings announcement on Monday, September, 25th 2017. View Earnings Estimates for Nymox Pharmaceutical Corporation.

Who are some of Nymox Pharmaceutical Corporation's key competitors?

Who owns Nymox Pharmaceutical Corporation stock?

Nymox Pharmaceutical Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (0.57%), Wedbush Securities Inc. (0.47%), TIAA CREF Investment Management LLC (0.15%), Bank of New York Mellon Corp (0.15%), Vanguard Group Inc. (0.14%) and California State Teachers Retirement System (0.10%). View Institutional Ownership Trends for Nymox Pharmaceutical Corporation.

Who bought Nymox Pharmaceutical Corporation stock? Who is buying Nymox Pharmaceutical Corporation stock?

Nymox Pharmaceutical Corporation's stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, TIAA CREF Investment Management LLC, Bank of New York Mellon Corp, Vanguard Group Inc., Wedbush Securities Inc., California State Teachers Retirement System, Schwab Charles Investment Management Inc. and Teachers Advisors LLC. View Insider Buying and Selling for Nymox Pharmaceutical Corporation.

How do I buy Nymox Pharmaceutical Corporation stock?

Shares of Nymox Pharmaceutical Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nymox Pharmaceutical Corporation's stock price today?

One share of Nymox Pharmaceutical Corporation stock can currently be purchased for approximately $3.89.


MarketBeat Community Rating for Nymox Pharmaceutical Corporation (NASDAQ NYMX)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  34 (Vote Underperform)
Total Votes:  64
MarketBeat's community ratings are surveys of what our community members think about Nymox Pharmaceutical Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Earnings by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Earnings History by Quarter for Nymox Pharmaceutical Corporation (NASDAQ NYMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/25/2017        
11/14/2014Q314($0.02)$0.08 millionViewN/AView Earnings Details
11/13/2013Q3($0.03)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.05)($0.03)$0.78 million$0.18 millionViewN/AView Earnings Details
11/14/2012Q312($0.06)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Insider Ownership Percentage: 54.00%
Institutional Ownership Percentage: 5.79%
Insider Trades by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Institutional Ownership by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Insider Trades by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/3/2017James George RobinsonDirectorBuy10,000$3.73$37,300.00View SEC Filing  
8/2/2017James George RobinsonDirectorBuy5,000$3.79$18,950.00View SEC Filing  
8/1/2017James George RobinsonDirectorBuy15,000$3.72$55,800.00View SEC Filing  
7/7/2017James George RobinsonDirectorBuy11,500$4.00$46,000.00View SEC Filing  
7/6/2017James George RobinsonDirectorBuy3,000$3.92$11,760.00View SEC Filing  
7/5/2017James George RobinsonDirectorBuy5,000$3.97$19,850.00View SEC Filing  
6/28/2017James George RobinsonDirectorBuy8,500$4.09$34,765.00View SEC Filing  
6/26/2017James George RobinsonDirectorBuy15,000$3.80$57,000.00View SEC Filing  
6/21/2017James George RobinsonDirectorBuy15,000$3.77$56,550.00View SEC Filing  
6/20/2017James George RobinsonDirectorBuy5,000$3.76$18,800.00View SEC Filing  
6/19/2017James George RobinsonDirectorBuy5,000$3.79$18,950.00View SEC Filing  
5/30/2017James George RobinsonDirectorBuy54,500$3.81$207,645.00View SEC Filing  
3/8/2017James George RobinsonDirectorBuy50,000$3.59$179,500.00View SEC Filing  
8/10/2016James George RobinsonDirectorBuy500$2.47$1,235.00View SEC Filing  
8/4/2016James George RobinsonDirectorBuy7,000$3.41$23,870.00View SEC Filing  
7/29/2016James George RobinsonDirectorBuy22,500$3.86$86,850.00View SEC Filing  
7/20/2016James George RobinsonDirectorBuy10,000$3.33$33,300.00View SEC Filing  
7/7/2016James George RobinsonDirectorBuy20,000$3.28$65,600.00View SEC Filing  
6/29/2016James George RobinsonDirectorBuy17,500$3.53$61,775.00View SEC Filing  
6/24/2016James George RobinsonDirectorBuy22,500$2.97$66,825.00View SEC Filing  
5/13/2016James George RobinsonDirectorBuy28,010$2.31$64,703.10View SEC Filing  
5/3/2016James George RobinsonDirectorBuy6,990$2.36$16,496.40View SEC Filing  
4/29/2016James George RobinsonDirectorBuy15,000$2.27$34,050.00View SEC Filing  
4/15/2016James George RobinsonDirectorBuy39,500$2.39$94,405.00View SEC Filing  
4/1/2016James George RobinsonDirectorBuy20,500$2.40$49,200.00View SEC Filing  
3/24/2016James George RobinsonDirectorBuy40,000$2.29$91,600.00View SEC Filing  
1/12/2016James George RobinsonDirectorBuy20,000$2.44$48,800.00View SEC Filing  
1/8/2016James George RobinsonDirectorBuy95,000$2.90$275,500.00View SEC Filing  
12/30/2015James George RobinsonDirectorBuy5,000$3.38$16,900.00View SEC Filing  
12/29/2015James George RobinsonDirectorBuy14,000$3.55$49,700.00View SEC Filing  
12/28/2015James George RobinsonDirectorBuy6,000$3.79$22,740.00View SEC Filing  
12/23/2015James George RobinsonDirectorBuy29,854$3.54$105,683.16View SEC Filing  
12/18/2015James George RobinsonDirectorBuy63,334$3.56$225,469.04View SEC Filing  
12/11/2015James George RobinsonDirectorBuy46,812$3.51$164,310.12View SEC Filing  
12/4/2015James George RobinsonDirectorBuy110,000$3.44$378,400.00View SEC Filing  
9/3/2015James George RobinsonDirectorBuy100,000$2.25$225,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Latest Headlines for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Source:
DateHeadline
streetinsider.com logoNymox Pharma (NYMX) Says Its MAA For Fexapotide Triflutate was Validated - StreetInsider.com
www.streetinsider.com - September 15 at 7:03 AM
finance.yahoo.com logoNymox Announces New Symposium for Company's BPH Drug at American Urological Association Meeting October 5
finance.yahoo.com - September 15 at 7:03 AM
finance.yahoo.com logoNymox Application Validated:
finance.yahoo.com - September 15 at 7:03 AM
finance.yahoo.com logoAUA Meeting in Florida September 16 Postponed Due to Hurricane
finance.yahoo.com - September 12 at 7:40 AM
finance.yahoo.com logoETFs with exposure to Nymox Pharmaceutical Corp. : September 12, 2017
finance.yahoo.com - September 12 at 7:40 AM
finance.yahoo.com logoETFs with exposure to Nymox Pharmaceutical Corp. : August 31, 2017
finance.yahoo.com - September 1 at 6:37 AM
americanbankingnews.com logoNymox Pharmaceutical Corporation (NYMX) Lowered to Sell at ValuEngine
www.americanbankingnews.com - August 27 at 1:44 PM
finance.yahoo.com logoNymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 9:32 AM
finance.yahoo.com logoNymox Announces Private Placements of $3 Million
finance.yahoo.com - August 10 at 6:23 AM
nasdaq.com logoNymox Announces Symposium for Company's BPH Drug at ... - Nasdaq
www.nasdaq.com - August 8 at 2:39 AM
americanbankingnews.com logoNymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson Acquires 10,000 Shares
www.americanbankingnews.com - August 4 at 9:00 PM
americanbankingnews.com logoInsider Buying: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director Buys 5,000 Shares of Stock
www.americanbankingnews.com - August 4 at 9:00 PM
finance.yahoo.com logoETFs with exposure to Nymox Pharmaceutical Corp. : August 4, 2017
finance.yahoo.com - August 4 at 6:32 AM
americanbankingnews.com logoNymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson Acquires 15,000 Shares
www.americanbankingnews.com - August 1 at 8:21 PM
americanbankingnews.com logoNymox Pharmaceutical Corporation (NYMX) Director James George Robinson Buys 11,500 Shares
www.americanbankingnews.com - July 7 at 9:03 PM
americanbankingnews.com logoNymox Pharmaceutical Corporation (NYMX) Director James George Robinson Acquires 5,000 Shares
www.americanbankingnews.com - July 7 at 9:02 PM
americanbankingnews.com logoInsider Buying: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director Acquires 3,000 Shares of Stock
www.americanbankingnews.com - July 7 at 9:02 PM
thestreet.com logoCommit To Purchase Nymox Pharmaceutical Corp At $3, Earn 25% Using Options
www.thestreet.com - July 6 at 7:37 AM
finance.yahoo.com logoETFs with exposure to Nymox Pharmaceutical Corp. : July 4, 2017
finance.yahoo.com - July 5 at 9:08 AM
americanbankingnews.com logoNymox Pharmaceutical Corporation (NYMX) Director James George Robinson Acquires 8,500 Shares
www.americanbankingnews.com - June 29 at 8:36 PM
americanbankingnews.com logoInsider Buying: Nymox Pharmaceutical Corporation (NYMX) Director Purchases 15,000 Shares of Stock
www.americanbankingnews.com - June 26 at 7:18 PM
americanbankingnews.com logoInsider Buying: Nymox Pharmaceutical Corporation (NYMX) Director Acquires 5,000 Shares of Stock
www.americanbankingnews.com - June 21 at 10:46 PM
americanbankingnews.com logoJames George Robinson Buys 5,000 Shares of Nymox Pharmaceutical Corporation (NYMX) Stock
www.americanbankingnews.com - June 21 at 10:46 PM
americanbankingnews.com logoJames George Robinson Purchases 15,000 Shares of Nymox Pharmaceutical Corporation (NYMX) Stock
www.americanbankingnews.com - June 21 at 8:04 PM
finance.yahoo.com logoSexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials
finance.yahoo.com - May 31 at 7:18 PM
americanbankingnews.com logoNymox Pharmaceutical Co. (NYMX) Director James George Robinson Purchases 54,500 Shares
www.americanbankingnews.com - May 31 at 4:26 PM
globenewswire.com logoSexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical ... - GlobeNewswire (press release)
globenewswire.com - May 31 at 11:29 AM
finance.yahoo.com logoNymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 10:18 AM
finance.yahoo.com logoNymox reports 1Q loss
finance.yahoo.com - May 16 at 10:05 AM
globenewswire.com logoNYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 ...
globenewswire.com - May 12 at 12:29 AM
feeds.benzinga.com logoNYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT
feeds.benzinga.com - May 10 at 11:37 AM
finance.yahoo.com logoNYMOX Files For Approval of First In Class Prostate Drug in Europe: Company To Hold Teleconference Wednesday May 10 at 4:30 EDT
finance.yahoo.com - May 8 at 12:13 PM
americanbankingnews.com logoNymox Pharmaceutical (NYMX) Earning Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - May 4 at 12:08 PM
globenewswire.com logoNYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe - GlobeNewswire (press release)
globenewswire.com - May 3 at 8:06 PM
finance.yahoo.com logoNYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe
finance.yahoo.com - May 3 at 8:06 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Likely to Affect Nymox Pharmaceutical (NYMX) Stock Price
www.americanbankingnews.com - April 23 at 10:44 PM
americanbankingnews.com logoNymox Pharmaceutical (NYMX) Earning Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - April 21 at 12:33 AM
finance.yahoo.com logoNymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017
finance.yahoo.com - April 7 at 11:39 AM
finance.yahoo.com logoPacific Biosciences of California and Nymox Pharmaceutical Move Up On Bullish Product Environments
finance.yahoo.com - March 30 at 7:15 PM
americanbankingnews.com logoNymox Pharmaceutical Co. (NYMX) Director James George Robinson Purchases 50,000 Shares
www.americanbankingnews.com - March 29 at 10:34 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Vertex Pharma, Morgan Stanley, F5, Exar, Tonix Pharma, Vertex - Nasdaq
www.nasdaq.com - March 29 at 7:38 PM
finance.yahoo.com logoNymox Provides Update on Fexapotide Development
finance.yahoo.com - March 29 at 7:38 PM
finance.yahoo.com logo10:46 am Nymox Pharma provides update, says now expects to submit its initial filing seeking approval for Fexapotide Triflutate in the next few weeks
finance.yahoo.com - March 29 at 7:38 PM
finance.yahoo.com logoIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Nymox Pharmaceutical Corporation and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - March 1 at 10:26 AM
finance.yahoo.com logoNymox Pharmaceutical Corporation Investigated For Securities Fraud By Block & Leviton After Report Reveals Pervasive Misconduct By The Company
finance.yahoo.com - March 1 at 10:26 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nymox Pharmaceutical Corporation (NYMX)
finance.yahoo.com - March 1 at 10:26 AM
247wallst.com logo5 Biohealth Stocks Rising 10% or More on News
247wallst.com - March 1 at 10:26 AM
thestreet.com logoNymox Pharmaceuticals (NYMX) Stock Surges on Prostate Drug Progress
www.thestreet.com - March 1 at 10:26 AM
thestreet.com logoNymox Pharmaceuticals (NYMX) Stock Surges on Long-Term Prostate Drug Trial Success
www.thestreet.com - March 1 at 10:26 AM
finance.yahoo.com logoWhy Nymox Pharma (NYMX) Closed the Day Up 83%
finance.yahoo.com - March 1 at 10:26 AM

Social

Chart

Nymox Pharmaceutical Corporation (NYMX) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff